SB Augmentin Composition Patent May Protect U.S. Sales Until 2017
Executive Summary
A formulation patent issued for SmithKline Beecham's flagship antibiotic Augmentin may protect the U.S. market for the product until 2017.
You may also be interested in...
GSK Formula For Older Products: "Clever" Patent Defenses, Cutting SKUs
GlaxoSmithKline's next phase of global streamlining will focus on reducing the number of formulations of older brands that it produces.
GSK Formula For Older Products: "Clever" Patent Defenses, Cutting SKUs
GlaxoSmithKline's next phase of global streamlining will focus on reducing the number of formulations of older brands that it produces.
GSK Augmentin ES Needs "Boundary" On Resistant Strains Covered, FDA Cmte
GlaxoSmithKline should indicate an upper "boundary" of penicillin resistance that its antibiotic Augmentin ES is expected to effectively treat, FDA's Anti-Infective Drugs Advisory Committee suggested Jan. 30.